X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (178304) 178304
Patent (986) 986
Book Chapter (916) 916
Book / eBook (104) 104
Newspaper Article (101) 101
Magazine Article (41) 41
Publication (18) 18
Government Document (14) 14
Conference Proceeding (13) 13
Dissertation (7) 7
Reference (4) 4
Streaming Video (3) 3
Trade Publication Article (3) 3
Web Resource (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (173831) 173831
science & technology (155942) 155942
life sciences & biomedicine (142987) 142987
female (64372) 64372
animals (60318) 60318
oncology (55583) 55583
male (39523) 39523
middle aged (35395) 35395
cancer (33657) 33657
adult (29459) 29459
cell biology (29359) 29359
aged (28592) 28592
cell line, tumor (25223) 25223
mice (25127) 25127
research (23554) 23554
breast cancer (21301) 21301
biochemistry & molecular biology (20841) 20841
signal transduction (20460) 20460
proteins (19214) 19214
gene expression (18858) 18858
analysis (18813) 18813
prognosis (17065) 17065
tumors (16637) 16637
care and treatment (16555) 16555
health aspects (15482) 15482
research article (14984) 14984
immunohistochemistry (14721) 14721
genetic aspects (14719) 14719
mutation (14661) 14661
apoptosis (13867) 13867
medicine & public health (13866) 13866
metastasis (13688) 13688
breast neoplasms - pathology (13497) 13497
epidermal growth factor (13351) 13351
medicine (12796) 12796
science & technology - other topics (12502) 12502
aged, 80 and over (12489) 12489
chemotherapy (12426) 12426
kinases (11899) 11899
cells, cultured (11742) 11742
pathology (11692) 11692
multidisciplinary sciences (11394) 11394
cell proliferation (11242) 11242
physiological aspects (10808) 10808
antineoplastic agents - therapeutic use (10786) 10786
gene expression regulation, neoplastic (10589) 10589
phosphorylation (10511) 10511
pharmacology & pharmacy (10426) 10426
development and progression (10043) 10043
treatment outcome (9890) 9890
medicine, research & experimental (9685) 9685
research & experimental medicine (9681) 9681
cell line (9444) 9444
receptor, epidermal growth factor - metabolism (9256) 9256
immunology (9206) 9206
risk factors (9200) 9200
breast neoplasms - metabolism (8934) 8934
stem cells (8871) 8871
biology (8806) 8806
abridged index medicus (8800) 8800
surgery (8484) 8484
science (8450) 8450
antineoplastic agents - pharmacology (8429) 8429
cancer therapies (8282) 8282
lung cancer (8086) 8086
studies (8084) 8084
neoplasm staging (8048) 8048
dermatology (7970) 7970
review (7815) 7815
breast neoplasms - drug therapy (7778) 7778
cell proliferation - drug effects (7705) 7705
signal transduction - drug effects (7585) 7585
breast neoplasms - genetics (7413) 7413
cancer research (7333) 7333
genes (7237) 7237
medical research (7155) 7155
receptor, epidermal growth factor - genetics (7060) 7060
lung neoplasms - pathology (7036) 7036
patients (6998) 6998
tumor cells, cultured (6983) 6983
genetics & heredity (6931) 6931
retrospective studies (6665) 6665
lung neoplasms - drug therapy (6608) 6608
lung neoplasms - genetics (6579) 6579
biomarkers (6440) 6440
medical prognosis (6393) 6393
apoptosis - drug effects (6353) 6353
inflammation (6285) 6285
growth factors (6240) 6240
antineoplastic combined chemotherapy protocols - therapeutic use (6235) 6235
cell cycle (6050) 6050
rodents (6011) 6011
blotting, western (5896) 5896
receptor, erbb-2 - metabolism (5896) 5896
mice, nude (5829) 5829
hematology, oncology and palliative medicine (5795) 5795
physiology (5778) 5778
genetics (5761) 5761
biomedicine (5709) 5709
biochemistry (5705) 5705
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (35) 35
Collection Dvlpm't (Acquisitions) - Vendor file (8) 8
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (5) 5
UofT at Mississauga - Stacks (4) 4
UofT at Scarborough - Stacks (3) 3
Online Resources - Online (2) 2
St. Michael's Hospital - Stacks (2) 2
Baycrest Hospital - Stacks (1) 1
Credit Valley Hospital - Stacks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Gerstein Science - Circulation Desk (1) 1
Gerstein Science - Missing (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
Trillium Health Centre - Reserve desk (1) 1
Trillium Health Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (179692) 179692
Japanese (642) 642
Chinese (608) 608
French (383) 383
German (353) 353
Spanish (119) 119
Portuguese (115) 115
Russian (111) 111
Korean (59) 59
Norwegian (35) 35
Dutch (24) 24
Hungarian (23) 23
Polish (18) 18
Danish (15) 15
Czech (14) 14
Hebrew (11) 11
Croatian (10) 10
Italian (9) 9
Bulgarian (7) 7
Serbian (7) 7
Slovak (6) 6
Turkish (6) 6
Greek (5) 5
Slovenian (5) 5
Latin (4) 4
Lithuanian (4) 4
Arabic (3) 3
Finnish (3) 3
Romanian (3) 3
Swedish (3) 3
Estonian (2) 2
Amharic (1) 1
Bosnian (1) 1
Breton (1) 1
Persian (1) 1
Ukrainian (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer science, ISSN 1347-9032, 07/2016, Volume 107, Issue 7, pp. 1039 - 1046
...‐8201a is a human epidermal growth factor receptor 2 (HER2)‐targeting antibody–drug conjugate prepared using a novel linker... 
topoisomerase I inhibitor | T‐DM | HER2 | bystander killing | Antibody‐drug conjugate | T-DM | Antibody-drug conjugate | Life Sciences & Biomedicine | Oncology | Science & Technology | Receptor, ErbB-2 - genetics | Breast Neoplasms - immunology | Humans | Ado-Trastuzumab Emtansine | Stomach Neoplasms - pathology | Maytansine - pharmacology | Immunoconjugates - immunology | Breast Neoplasms - enzymology | Immunoconjugates - pharmacology | Topoisomerase I Inhibitors - pharmacology | Neoplasms - genetics | Antibodies, Monoclonal, Humanized - pharmacology | Female | Camptothecin - immunology | Receptor, ErbB-2 - immunology | Camptothecin - analogs & derivatives | Stomach Neoplasms - enzymology | Stomach Neoplasms - genetics | Maytansine - analogs & derivatives | Neoplasms - enzymology | Stomach Neoplasms - immunology | Animals | Breast Neoplasms - genetics | Bystander Effect - drug effects | Breast Neoplasms - pathology | Mice, Nude | Neoplasms - immunology | Cell Membrane Permeability - drug effects | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Antibodies, Monoclonal, Humanized - immunology | Neoplasms - pathology | Camptothecin - pharmacology | Maytansine - immunology | Trastuzumab | Viral antibodies | Epidermal growth factor | Imaging systems | Antibodies | Permeability | Drug therapy | Biopharmaceutics | Tumors | Antigens | Hematology | Laboratories | Toxicity | DNA topoisomerase | Polymerization | Clinical trials | Cytotoxicity | Breast cancer | ErbB-2 protein | Stomach cancer | Hypotheses | Antitumor agents | Xenografts | Antitumor activity | Lymphomas | Drug dosages | Payloads | Index Medicus | Original
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 05/2015, Volume 33, Issue 15, pp. 1688 - 1696
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 02/2011, Volume 29, Issue 4, pp. 398 - 405
Journal Article
The Journal of biological chemistry, ISSN 0021-9258, 03/2004, Volume 279, Issue 13, pp. 12755 - 12762
Epidermal growth factor receptor (EGFR) activation is absolutely required for cervical cell proliferation... 
Life Sciences & Biomedicine | Biochemistry & Molecular Biology | Science & Technology | Phosphorylation | Tumor Suppressor Protein p53 - biosynthesis | Humans | Immunoblotting | DNA-Binding Proteins - metabolism | Dose-Response Relationship, Drug | Cyclins - biosynthesis | Receptor, Epidermal Growth Factor - metabolism | Ribosomal Protein S6 Kinases, 90-kDa - metabolism | Flow Cytometry | Time Factors | Cell Division | Polyphenols | Female | Flavonoids - pharmacology | Proto-Oncogene Proteins | Catechin - pharmacology | Protein-Serine-Threonine Kinases - metabolism | Phenols - pharmacology | In Situ Nick-End Labeling | Uterine Cervical Neoplasms - enzymology | Signal Transduction | Cyclin-Dependent Kinase Inhibitor p21 | Uterine Cervical Neoplasms - drug therapy | Cell Cycle Proteins - biosynthesis | Precipitin Tests | Cyclin-Dependent Kinase Inhibitor p27 | Proto-Oncogene Proteins c-akt | Transcription Factors - metabolism | Tea | Carrier Proteins - metabolism | Cell Cycle | Cell Line, Tumor | Catechin - analogs & derivatives | Forkhead Box Protein O1 | Cyclin E - metabolism | Enzyme Activation | HeLa Cells | Antineoplastic Agents, Phytogenic - pharmacology | Tumor Suppressor Proteins - biosynthesis | Forkhead Transcription Factors | bcl-Associated Death Protein | Mitogen-Activated Protein Kinase 3 | Apoptosis | Mitogen-Activated Protein Kinase 1 - metabolism | Mitogen-Activated Protein Kinases - metabolism | Index Medicus
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 11/2009, Volume 27, Issue 33, pp. 5529 - 5537
Purpose TAnDEM is the first randomized phase III study to combine a hormonal agent and trastuzumab without chemotherapy as treatment for human epidermal growth factor receptor 2 (HER2... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Receptors, Estrogen - blood | Triazoles - administration & dosage | Triazoles - adverse effects | Confidence Intervals | Postmenopause - drug effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antibodies, Monoclonal, Humanized | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Adenocarcinoma - metabolism | Statistics, Nonparametric | Aged, 80 and over | Female | Drug Administration Schedule | Administration, Oral | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Adenocarcinoma - secondary | Biomarkers, Tumor - blood | Disease-Free Survival | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Breast Neoplasms - pathology | Survival Analysis | Breast Neoplasms - mortality | Aged | Infusions, Intravenous | Nitriles - adverse effects | Receptors, Progesterone - blood | Receptor, ErbB-2 - blood | Trastuzumab | Adenocarcinoma - mortality | Index Medicus
Journal Article